India's Curadev bags Roche deal in hot IDO inhibitor space
This article was originally published in Scrip
Executive Summary
A young Indian small molecule discovery firm appears to have caught the fancy of none less than oncology giant, Roche, in the high potential indoleamine-2,3-dioxygenase-1 (IDO-1) inhibitor space.